Is Neuropace Stock a Good Investment?
Neuropace Investment Advice | NPCE |
- Examine Neuropace's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Neuropace's leadership team and their track record. Good management can help Neuropace navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Neuropace's business and its evolving consumer preferences.
- Compare Neuropace's performance and market position to its competitors. Analyze how Neuropace is positioned in terms of product offerings, innovation, and market share.
- Check if Neuropace pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Neuropace's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Neuropace stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Neuropace is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Neuropace Stock
Researching Neuropace's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 62.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.93. Neuropace had not issued any dividends in recent years.
To determine if Neuropace is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Neuropace's research are outlined below:
| Neuropace had very high historical volatility over the last 90 days | |
| Neuropace has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 79.91 M. Net Loss for the year was (27.14 M) with profit before overhead, payroll, taxes, and interest of 59.09 M. | |
| Neuropace currently holds about 92.41 M in cash with (17.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72. | |
| Roughly 62.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Cantor Fitzgerald maintains Overweight on NeuroPace stock - Investing.com India |
Neuropace Quarterly Liabilities And Stockholders Equity |
|
Neuropace uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Neuropace. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neuropace's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Neuropace's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Neuropace's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-13 | 2024-06-30 | -0.3 | -0.26 | 0.04 | 13 | ||
2021-11-10 | 2021-09-30 | -0.3 | -0.34 | -0.04 | 13 | ||
2025-03-03 | 2024-12-31 | -0.2233 | -0.18 | 0.0433 | 19 | ||
2023-05-04 | 2023-03-31 | -0.46 | -0.41 | 0.05 | 10 | ||
2024-11-12 | 2024-09-30 | -0.27 | -0.19 | 0.08 | 29 | ||
2024-03-05 | 2023-12-31 | -0.31 | -0.23 | 0.08 | 25 | ||
2022-08-11 | 2022-06-30 | -0.44 | -0.52 | -0.08 | 18 | ||
2023-08-08 | 2023-06-30 | -0.46 | -0.36 | 0.1 | 21 |
Neuropace Target Price Consensus
Neuropace target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Neuropace's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Strong Buy |
Most Neuropace analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Neuropace stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Neuropace, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationNeuropace Target Price Projection
Neuropace's current and average target prices are 11.48 and 16.17, respectively. The current price of Neuropace is the price at which Neuropace is currently trading. On the other hand, Neuropace's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Neuropace Target Price
Neuropace Analyst Ratings
Neuropace's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Neuropace stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Neuropace's financials, market performance, and future outlook by experienced professionals. Neuropace's historical ratings below, therefore, can serve as a valuable tool for investors.Know Neuropace's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Neuropace is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neuropace backward and forwards among themselves. Neuropace's institutional investor refers to the entity that pools money to purchase Neuropace's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 323 K | Fmr Inc | 2024-12-31 | 249.7 K | Northern Trust Corp | 2024-12-31 | 184.8 K | State Street Corp | 2024-12-31 | 148.3 K | Jane Street Group Llc | 2024-12-31 | 100.1 K | Renaissance Technologies Corp | 2024-12-31 | 86.3 K | Jpmorgan Chase & Co | 2024-12-31 | 64.8 K | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 57.1 K | Gsa Capital Partners Llp | 2024-12-31 | 56.4 K | Kck Ltd | 2024-12-31 | 5.3 M | Orbimed Advisors, Llc | 2024-12-31 | 3.4 M |
Neuropace's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 382.58 M.Market Cap |
|
Neuropace's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.30) | |
| Return On Capital Employed | (0.27) | (0.29) | |
| Return On Assets | (0.29) | (0.30) | |
| Return On Equity | (3.39) | (3.22) |
Determining Neuropace's profitability involves analyzing its financial statements and using various financial metrics to determine if Neuropace is a good buy. For example, gross profit margin measures Neuropace's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Neuropace's profitability and make more informed investment decisions.
Please note, the presentation of Neuropace's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neuropace's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Neuropace's management manipulating its earnings.
Evaluate Neuropace's management efficiency
Neuropace has return on total asset (ROA) of (0.1339) % which means that it has lost $0.1339 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8935) %, meaning that it created substantial loss on money invested by shareholders. Neuropace's management efficiency ratios could be used to measure how well Neuropace manages its routine affairs as well as how well it operates its assets and liabilities. As of March 20, 2025, Return On Tangible Assets is expected to decline to -0.3. In addition to that, Return On Capital Employed is expected to decline to -0.29. At present, Neuropace's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 2.8 M, whereas Non Currrent Assets Other are forecasted to decline to about 340.6 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.28 | 0.29 | |
| Tangible Book Value Per Share | 0.28 | 0.29 | |
| Enterprise Value Over EBITDA | (23.28) | (24.44) | |
| Price Book Value Ratio | 40.67 | 42.71 | |
| Enterprise Value Multiple | (23.28) | (24.44) | |
| Price Fair Value | 40.67 | 42.71 | |
| Enterprise Value | 385.8 M | 432.4 M |
Neuropace showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 2.071 |
Basic technical analysis of Neuropace Stock
As of the 20th of March, Neuropace secures the Risk Adjusted Performance of 0.045, mean deviation of 3.15, and Downside Deviation of 4.01. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neuropace, as well as the relationship between them. Please verify Neuropace value at risk, as well as the relationship between the semi variance and kurtosis to decide if Neuropace is priced some-what accurately, providing market reflects its recent price of 11.48 per share. Given that Neuropace has jensen alpha of 0.2598, we recommend you to check Neuropace's last-minute market performance to make sure the company can sustain itself at a future point.Neuropace's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neuropace insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neuropace's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neuropace insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Neuropace's Outstanding Corporate Bonds
Neuropace issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neuropace uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neuropace bonds can be classified according to their maturity, which is the date when Neuropace has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US64128XAE04 Corp BondUS64128XAE04 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Neuropace's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Neuropace's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.045 | |||
| Market Risk Adjusted Performance | 0.1217 | |||
| Mean Deviation | 3.15 | |||
| Semi Deviation | 3.8 | |||
| Downside Deviation | 4.01 | |||
| Coefficient Of Variation | 2379.23 | |||
| Standard Deviation | 3.94 | |||
| Variance | 15.51 | |||
| Information Ratio | 0.0585 | |||
| Jensen Alpha | 0.2598 | |||
| Total Risk Alpha | 0.488 | |||
| Sortino Ratio | 0.0574 | |||
| Treynor Ratio | 0.1117 | |||
| Maximum Drawdown | 17.98 | |||
| Value At Risk | (6.82) | |||
| Potential Upside | 5.89 | |||
| Downside Variance | 16.11 | |||
| Semi Variance | 14.47 | |||
| Expected Short fall | (3.31) | |||
| Skewness | (0.07) | |||
| Kurtosis | (0.04) |
| Risk Adjusted Performance | 0.045 | |||
| Market Risk Adjusted Performance | 0.1217 | |||
| Mean Deviation | 3.15 | |||
| Semi Deviation | 3.8 | |||
| Downside Deviation | 4.01 | |||
| Coefficient Of Variation | 2379.23 | |||
| Standard Deviation | 3.94 | |||
| Variance | 15.51 | |||
| Information Ratio | 0.0585 | |||
| Jensen Alpha | 0.2598 | |||
| Total Risk Alpha | 0.488 | |||
| Sortino Ratio | 0.0574 | |||
| Treynor Ratio | 0.1117 | |||
| Maximum Drawdown | 17.98 | |||
| Value At Risk | (6.82) | |||
| Potential Upside | 5.89 | |||
| Downside Variance | 16.11 | |||
| Semi Variance | 14.47 | |||
| Expected Short fall | (3.31) | |||
| Skewness | (0.07) | |||
| Kurtosis | (0.04) |
Consider Neuropace's intraday indicators
Neuropace intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Neuropace stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Neuropace Corporate Filings
F4 | 5th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 4th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 18th of February 2025 Other Reports | ViewVerify | |
| 11th of February 2025 Other Reports | ViewVerify |
Neuropace Stock media impact
Far too much social signal, news, headlines, and media speculation about Neuropace that are available to investors today. That information is available publicly through Neuropace media outlets and privately through word of mouth or via Neuropace internal channels. However, regardless of the origin, that massive amount of Neuropace data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neuropace news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neuropace relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neuropace's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neuropace alpha.
Neuropace Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Neuropace can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Neuropace Historical Investor Sentiment
Investor biases related to Neuropace's public news can be used to forecast risks associated with an investment in Neuropace. The trend in average sentiment can be used to explain how an investor holding Neuropace can time the market purely based on public headlines and social activities around Neuropace. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Neuropace's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Neuropace and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Neuropace news discussions. The higher the estimate score, the more favorable the investor's outlook on Neuropace.
Neuropace Corporate Management
| Irina Ridley | Chief Secretary | Profile | |
| Chi Nguyen | VP Marketing | Profile | |
| Kelley Nicholas | Vice Sales | Profile | |
| Michael Favet | CEO Pres | Profile | |
| Katie Keller | Vice Marketing | Profile | |
| Martha MD | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share | Quarterly Revenue Growth 0.192 | Return On Assets | Return On Equity |
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Neuropace's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.